Real World Evidence Highlights Clinical Utility of Cxbladder
Cancer diagnostics company, Pacific Edge Limited (PEB: NZX) has today announced the publication of further real world evidence of significant gains in clinical utility from the commercial adoption of Cxbladder Monitor (CxbM) by several of New Zealand’s public healthcare providers. [read more]
We welcome press and media enquiries. For further assistance, please feel free to contact us.